Compare SLNG & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | KPTI |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.0M | 94.6M |
| IPO Year | N/A | 2013 |
| Metric | SLNG | KPTI |
|---|---|---|
| Price | $4.55 | $6.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $10.00 | ★ $22.17 |
| AVG Volume (30 Days) | 5.3K | ★ 177.9K |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | $72,270,000.00 | ★ $142,530,000.00 |
| Revenue This Year | $7.02 | $3.82 |
| Revenue Next Year | $7.68 | $3.18 |
| P/E Ratio | $89.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.29 | $3.51 |
| 52 Week High | $8.28 | $12.45 |
| Indicator | SLNG | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 55.12 |
| Support Level | $4.92 | $5.99 |
| Resistance Level | $5.17 | $7.48 |
| Average True Range (ATR) | 0.15 | 0.53 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 6.06 | 51.38 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.